

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 6185)

INSIDE INFORMATION

**PHASE III CLINICAL TRIAL FOR RECOMBINANT NOVEL
CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR)**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company is pleased to announce that the Company has initiated the phase III clinical trial for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (the “**Ad5-nCoV**”). The Company has entered into an agreement with NPO Petrovax Pharm, LLC (“**Petrovax**”), pursuant to which the Company and Petrovax will cooperate to conduct the phase III clinical trial for Ad5-nCoV in Russia. The Company and Petrovax have received the clinical trial application approval for Ad5-nCoV from the Ministry of Health of the Russian Federation and initiated enrollment of phase III clinical trial for Ad5-nCoV in Russia. In addition, the Company is currently driving the international multi-center phase III clinical trial for Ad5-nCoV and plans to conduct the phase III clinical trial for Ad5-nCoV in several countries.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: The safety and efficacy of Ad5-nCoV is subject to confirmation by clinical trials and we cannot guarantee that we will ultimately develop or market Ad5-nCoV successfully. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, September 2, 2020

As at the date of this announcement, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.